CSIMarket
 
Tactile Systems Technology Inc   (NASDAQ: TCMD)
 
Price: $21.8700 $-0.14 -0.636%
Day's High: $22.260000228881836 Week Perf: -4.83 %
Day's Low: $ 21.61 30 Day Perf: -24.22 %
Volume (M): 197,928 52 Wk High: $ 37.77
Volume (M$): $ 0 52 Wk Avg: $24.75
Open: $21.76 52 Wk Low: $13.14



 Market Capitalization (Millions $) 504
 Shares Outstanding (Millions) 23
 Employees 1,086
 Revenues (TTM) (Millions $) 350
 Net Income (TTM) (Millions $) 25
 Cash Flow (TTM) (Millions $) -7
 Capital Exp. (TTM) (Millions $) 4

Business Description


Tactile Systems Technology Inc. is a publicly traded medical device company focused on developing and marketing at-home therapy devices that improve circulation and reduce swelling, discomfort and pain for individuals with lymphedema, chronic venous insufficiency, and other conditions affecting the lymphatic and vascular systems.

Headquartered in Minneapolis, Minnesota, the company was founded in 1995 by a licensed physical therapist, and to date, it has continued to develop clinically proven, non-invasive, and cost-effective products that aid in the management of chronic diseases. Tactile Systems Technology primarily markets its products through direct sales and a network of distributors across the United States as well as partnering with healthcare professionals such as lymphedema and wound care therapists.

One of their primary products, the Flexitouche system, utilizes a pneumatic compression technology to simulate the hand motion of a lymphatic therapist or clinician performing various stages of manual lymph drainage. It is indicated for the treatment of lymphedema in the arms, legs or trunk, and has been clinically demonstrated to reduce swelling, increase limb mobility and reduce the risk of infection. Another product, the Entr' System, is a simplified and portable version of the Flexitouche system, and is intended for use by patients and caregivers in the home environment.

Tactile Systems Technology has a strong commitment to research and development, and as a result, the company has obtained multiple patents for its innovative technology. The company also collaborates with leading healthcare professionals and institutions to conduct research studies aimed at improving the quality of life for patients with chronic diseases.

In addition, Tactile Systems Technology has received numerous accolades and recognitions for its outstanding contribution to the medical device industry. These include being named Forbes' "Top 100 Public Companies in America" and "Top Small Cap Growth Companies" along with various industry awards, such as the "2017 Global Frost & Sullivan Award for Growth Excellence Leadership" in the compression therapy industry.

Overall, Tactile Systems Technology's mission is to improve the lives of individuals living with chronic diseases based on its strong belief in the power of science, innovation and committed partnership with patients, healthcare professionals and the community.


   Company Address: 3701 Wayzata Blvd, Suite 300 Minneapolis 55416 MN
   Company Phone Number: 355-5100   Stock Exchange / Ticker: NASDAQ TCMD


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
MDT        3.22% 
MMM   -3.32%    
NPCE        3.4% 
PDEX        17.34% 
SYK   -8.33%    
• View Complete Report
   



Clinical Study

Hope and Healing Flexitouch Plus Emerges as Revolutionary First-Line Treatment for Cancer-Related Lymphedema,

Published Wed, Oct 29 2025 4:54 PM UTC

In a groundbreaking presentation at the 102nd Annual Fall Conference of the American Congress of Rehabilitation Medicine (ACRM), Tactile Systems Technology, Inc., known as Tactile Medical (Nasdaq: TCMD), showcased promising new clinical data underscoring the effectiveness of the Flexitouch Plus device. The study provided critical insights into the sustained clinical benefits...

Management Changes

Tactile Medicals Bold Moves: New Board Appointment and Cutting-Edge Lymphedema Technology Signal Strategic Growth in Chronic Care Management,

Published Mon, Jan 13 2025 1:00 PM UTC

Tactile Medical s Strategic Moves: A New Board Member and Innovative Therapies Signal Growth Amid Rising Demand for Chronic Care SolutionsBy CSI Market Reporter MINNEAPOLIS, MN — On January 13, 2025, Tactile Systems Technology, Inc. (Nasdaq: TCMD), a rapidly evolving player in the medical technology sector, announced the appointment of Laura King to its Board of Dir...

Product Service News

In a significant breakthrough in the treatment of lymphedema, Tactile Medical has announced the launch of i...

Published Wed, Oct 2 2024 12:00 PM UTC

Innovative Technology to Address Upper Extremity Lymphedema: Tactile Medical Unveils Next-Generation Nimbl Platform In a significant breakthrough in the treatment of lymphedema, Tactile Medical has announced the launch of its next-generation Nimbl platform. This state-of-the-art technology is set to transform the care provided to patients suffering from upper extremity lymph...

Clinical Study

Advanced Pneumatic Compression Therapy Yields Positive Results for Lymphedema Patients in Largest U.S. Clinical Trial

Published Wed, Sep 25 2024 12:01 PM UTC

Summary : Tactile Medical s Flexitouch System demonstrates significant improvements and high compliance in lymphedema treatment.Tactile Medical has announced groundbreaking results from the largest U.S. prospective clinical trial ever conducted on the treatment of lymphedema using advanced pneumatic compression device therapy. The trial, which evaluated the efficacy of the F...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 20.25
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 1.44
Price to Sales (Expected) -
Price to Book 2.25
PEG (TTM) 0.27

Financial Strength Current
Quick Ratio 1.83
Working Capital Ratio 4.12
Leverage Ratio (MRQ) 0.25
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 1.08 $
Revenues (TTM) 15.19 $
Cash Flow (TTM) -
Cash 3.03 $
Book Value 9.71 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 322,577
Net Income per Employee (TTM) 22,896
Receivable Turnover Ratio (TTM) 8.62
Inventory Turnover Ratio (TTM) 5.12
Asset Turnover Ratio (TTM) 1.29

Profitability Ratios Current
Gross Margin (MRQ) 76.25 %
Operating Margin (MRQ) 7.97 %
Net Margin (MRQ) 9.08 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) 33.44 %

Management Effectiveness Current
Return On Assets (TTM) 9.17 %
Return On Investment (TTM) 10.58 %
Return On Equity (TTM) 11.49 %
Dividend Yield -
Pay out Ratio (TTM) -



Tactile Systems Technology Inc's Segments
Product    167.4 % of total Revenue
Rental Product Service    20.43 % of total Revenue
Lymphedema products    158.52 % of total Revenue
Airway clearance products    29.31 % of total Revenue

  Tactile Systems Technology Inc Outlook

On February 20 2024 the Tactile Systems Technology Inc provided following guidance

On February 20, 2024, Tactile Systems Technology, Inc. reported their financial results for the fourth quarter and full year of 2023. The company saw a significant increase in their full year revenue, with an 11% growth compared to the previous year. Additionally, their full year net income surged by 260%, showcasing the company's strong financial performance. The adjusted EBITDA also saw a notable increase of 62% for the full year.

The company also introduced their outlook for the full year of 2024, indicating a positive trajectory for their financial performance. With the impressive growth seen in 2023, Tactile Systems Technology, Inc. is poised to continue their success and potentially achieve even...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.